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background
Average real variability (ARV) is a recently proposed index for short-
term blood pressure (BP) variability. We aimed to determine the mini-
mum number of BP readings required to compute ARV without loss of 
prognostic information.
methods
ARV was calculated from a discovery dataset that included 24-hour ambu-
latory BP measurements for 1,254 residents (mean age  =  56.6  years; 
43.5% women) of Copenhagen, Denmark. Concordance between ARV 
from full (≥80 BP readings) and randomly reduced 24-hour BP record-
ings was examined, as was prognostic accuracy. A  test dataset that 
included 5,353 subjects (mean age  =  54.0  years; 45.6% women) with 
at least 48 BP measurements from 11 randomly recruited population 
cohorts was used to validate the results.
results
In the discovery dataset, a minimum of 48 BP readings allowed an 
accurate assessment of the association between cardiovascular risk 
and ARV. In the test dataset, over 10.2 years (median), 806 participants 
died (335 cardiovascular deaths, 206 cardiac deaths) and 696 experi-
enced a major fatal or nonfatal cardiovascular event. Standardized 
multivariable-adjusted hazard ratios (HRs) were computed for asso-
ciations between outcome and BP variability. Higher diastolic ARV in 
24-hour ambulatory BP recordings predicted (P < 0.01) total (HR = 1.12), 
cardiovascular (HR = 1.19), and cardiac (HR = 1.19) mortality and fatal 
combined with nonfatal cerebrovascular events (HR = 1.16). Higher sys-
tolic ARV in 24-hour ambulatory BP recordings predicted (P < 0.01) total 
(HR = 1.12), cardiovascular (HR = 1.17), and cardiac (HR = 1.24) mortality.
conclusions
Forty-eight BP readings over 24 hours were observed to be adequate to 
compute ARV without meaningful loss of prognostic information.
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Average real variability (ARV) is a recently proposed index 
to represent short-term, reading-to-reading, within-subject 
variability in blood pressure (BP).1 ARV attempts to correct 
for the limitations of the commonly used standard devia-
tion (SD), which accounts only for the dispersion of values 
around the mean, and not for the order of the BP readings.1–3
Several recent studies reported on the association between 
cardiovascular outcome and BP variability as assessed by 
24-hour ambulatory BP monitoring.1,2,4–6 Most of these 
studies included a small (n < 350) general1,6 or hypertensive 
population5 with a high percentage (>70%) of valid BP read-
ings obtained at intervals ranging from 151,5 to 304,6 minutes 
during daytime and from 301,5 to 604,6 minutes during night-
time. Participants with fewer than 32,6 57,1 or 595 BP read-
ings during the 24-hour monitoring period were excluded 
from these studies. The study with the largest number of par-
ticipants (n = 8,938), taken from the International Database 
on Ambulatory Blood Pressure Monitoring in Relation to 
Cardiovascular Outcomes (IDACO),7 excluded subjects 
that had less than 10  daytime or 5 nighttime BP readings 
or missing BP measurements during 3 consecutive hours.2 
However, none of the aforementioned studies considered 
the minimum number of BP readings required to estimate 
BP variability in an accurate manner. The aim of our study 
was to use a dataset of 1,254 IDACO subjects with at least 80 
ambulatory BP readings to determine an adequate number 
of BP readings needed to calculate ARV. We took advantage 
of the prospective design of IDACO to determine such num-
ber based on outcome data. The results were then validated 
using a test dataset with a larger number of subjects.
METHODS
Study population
At the time of writing this report, the IDACO database 
included 12,722 participants from 12 randomly recruited 
population cohorts.8–17 The Copenhagen cohort,8,18,19 for 
which ambulatory BP was recorded at 15-minute intervals 
from 7:00 am to 11:00 pm, and at 30-minute intervals from 
11:00 pm to 7:00 am, was selected as the discovery dataset 
for this study. The Copenhagen cohort included 2,311 sub-
jects equally distributed among the 2 sexes and among 4 age 
groups (41, 51, 61, and 71 years). Subjects with incomplete 
ambulatory BP recordings (<80 readings during 24 hours) 
were excluded (n  =  1,057), leaving 1,254 subjects for the 
discovery analysis. The results were tested for prognostic 
accuracy, using a larger sample of IDACO participants (test 
dataset). The test dataset included 5,353 IDACO subjects, 
who (i) were at least 18 years old, (ii) had at least 10 day-
time readings, 5 nighttime readings, and 48 readings over 24 
hours, and (iii) were not included in the discovery dataset.
BP measurement
A detailed description of the methods employed for con-
ventional and ambulatory BP monitoring is provided in the 
Supplementary Data. Hypertension was defined as a conven-
tional BP of at least 140 mm Hg systolic or 90 mm Hg dias-
tolic, or the use of antihypertensive drugs.20 The devices used 
in IDACO all passed validation and were programmed to 
obtain readings at 30-minute intervals throughout the whole 
day, or at intervals ranging 15–30 minutes during daytime 
and 30–60 minutes at night. Within individual subjects, the 
means of the ambulatory BP were weighted by the interval 
between readings. ARV over 24 hours was calculated using 
the following formula:
ARV
w
w BP BP
k k
n
k k k= × −∑ ∑= −
1
2
1
where n is the number of BP readings and wk is the time 
interval between BPk and BPk-1.1,2
Ascertainment of events
We ascertained vital status and the incidence of fatal and 
nonfatal diseases from the appropriate sources in each coun-
try, as described in previous publications.1,7,9,12,13,15 Fatal and 
nonfatal stroke did not include transient ischemic attacks. 
Cardiac events encompassed death from ischemic heart dis-
ease, sudden death, fatal and nonfatal heart failure, nonfatal 
myocardial infarction, and coronary revascularization. The 
composite cardiovascular endpoint included all aforemen-
tioned endpoints plus cardiovascular mortality. In all out-
come analyses, we only considered the first event within each 
category. The cardiovascular endpoints and the International 
Classification of Disease code numbers used to differentiate 
the events are available in Supplementary Table S1.
Statistical analysis
For database management and statistical analyses, we 
used SAS software, version 9.1.3 (SAS Institute, North 
Carolina, USA) and MATLAB software, version R2009a 
(MathWorks, Massachusetts, USA). Statistical significance 
was α < 0.05 on 2-tailed tests. For comparison of means 
and proportions, we applied the large-sample z test and the 
χ2statistic, respectively. In the discovery dataset, we randomly 
excluded 8, 16, 24, 32, 40, and 48 BP readings from each full 
ambulatory recording, generating reduced recordings with 
72, 64, 56, 48, 40, and 32 readings. Each reduction was based 
on the original full recording and used a different random 
seed. In an attempt to approximate the effect of missed 
readings, we did not eliminate BP measurements during the 
first or last hour of the ambulatory readings, and we did not 
eliminate more than 4 consecutive daytime or 2 consecutive 
nighttime readings. We quantified concordance between 
ARV calculated from full and reduced recordings using 
Pearson’s correlation coefficient, repeatability, and relative 
repeatability coefficients.21–23 The repeatability coefficient 
was defined as twice the SD of the within-subject difference 
between ARV calculated from full and reduced recordings. 
The relative repeatability coefficient was the repeatability 
coefficient expressed as a percentage of the maximal 
variability (4 times the SD of ARV averaged across the full 
and reduced recordings). Higher values of repeatability and 
relative repeatability coefficients indicate lower concordance.
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We used the Cox proportional hazard regression model 
to compute standardized hazard ratios (HRs), which 
express the risk for an increase by 1 SD in the independ-
ent variables. The HRs in the discovery dataset were initially 
computed adjusting only for sex and age, the most signifi-
cant independent cardiovascular predictors for this cohort 
(P  <  0.001), because the original Copenhagen Cohort was 
sampled with stratifying for sex and 4 age groups. The prog-
nostic information contributed by ARV based on reduced 
recordings was considered accurate if the standardized HR 
remained significant (P ≤ 0.05) and ≥1.10. We plotted the 
10-year risk (expressed as a percentage) of all-cause mortal-
ity and the composite cardiovascular endpoint in relation to 
ARV calculated from full and reduced recordings, standard-
ized to the mean distribution of sex and age in the discovery 
dataset. In the test dataset, further adjustments were applied 
for cohort, body mass index, serum cholesterol, smoking 
status, alcohol intake, history of cardiovascular disease, and 
treatment with antihypertensive drugs. Additionally, in fully 
adjusted models, we accounted for 24-hour BP. Finally, we 
calculated the generalized R2, which is a measure for the 
refinement of the risk prediction by adding covariables to 
the Cox model.24
RESULTS
Discovery dataset
The Copenhagen sample of 1,254 subjects included 545 
(43.5%) women and 569 (45.4%) individuals with hyper-
tension on conventional BP measurements, of whom 192 
(33.7%) were taking antihypertensive medication (Table 1). 
Mean age (±SD) was 56.6 ± 10.4 years, and body mass index 
averaged 25.8 ± 3.7 kg/m2. At enrollment, 75 (6.0%) par-
ticipants had a history of cardiovascular disease, 47 (3.8%) 
had diabetes mellitus, 539 (43.0%) were smokers, and 1,081 
(86.2%) reported intake of alcohol. Mean 24-hour BP was 
128.9 ± 12.8 mm Hg systolic and 75.9 ± 8.4 mm Hg diastolic.
Median follow-up time for the Copenhagen cohort was 
12.4  years. During 14,246 person-years of follow-up, 235 
participants died (16.5 per 1,000 person-years), and 171 sub-
jects experienced a fatal or nonfatal cardiovascular compli-
cation (12.4 per 1,000 person-years). Mortality included 76 
cardiovascular deaths, 152 noncardiovascular deaths, 2 renal 
deaths, and 5 deaths of unknown cause. The first occurring 
cardiovascular events consisted of 7 fatal strokes, 36 nonfa-
tal strokes, 46 nonfatal myocardial infarctions, 1 coronary 
Table 1. Baseline characteristics of participants enrolled in the discovery and test datbases
Discovery cohort Test cohort
Women Men Women Men
Number of subjects, no. (%) 545 709 2,440 2,913
 Smokers 221 (40.6) 318 (44.9) 499 (20.6) 963 (33.5)
 Use of alcohol 419 (77.7) 662 (93.6) 855 (36.0) 1,756 (71.2)
 Hypertension 231 (42.4) 338 (47.7) 1,040 (42.6) 1,502 (51.6)
 On antihypertensive treatment 97 (17.8) 95 (13.4) 500 (20.6) 632 (21.8)
 Diabetes mellitus 15 (2.8) 32 (4.5) 156 (6.4) 234 (8.0)
 Cardiovascular disorders 23 (4.2) 52 (7.3) 431 (17.7) 436 (15.0)
Mean characteristic (SD)
 Age, y 56.4 (10.3) 56.7 (10.5) 51.2 (15.5)  56.4 (16.2)
 Body mass index, kg/m2 25.2 (4.0)  26.3 (3.4) 25.3 (4.9)  25.8 (3.9)
Conventional blood pressure
 Systolic, mm Hg 130.1 (19.7) 133.4 (19.2) 132.7 (27.5) 138.1 (22.9)
 Diastolic, mm Hg 81.8 (10.7) 84.8 (11.1) 78.9 (12.1) 82.3 (11.5)
24-h blood pressure
 Systolic, mm Hg 126.4 (12.8) 130.7 (12.4) 121.5 (13.8) 128.1 (14.4)
 Diastolic, mm Hg 73.2 (8.0) 77.9 (8.1) 71.8 (8.1) 75.5 (8.4)
24-h average real variability
 Systolic, mm Hg 11.7 (2.4) 11.8 (2.5) 10.5 (3.2) 11.4 (3.4)
 Diastolic, mm Hg 7.6 (1.3) 7.9 (1.4) 8.0 (2.4) 8.8 (2.8)
24-h heart rate, beats/min 74.4 (8.0) 71.0 (8.8) 73.6 (8.4)  70.0 (9.4)
Serum cholesterol, mg/dl 6.3 (1.1) 6.1 (1.1) 5.6 (1.2)  5.6 (1.2)
Hypertension was a conventional blood pressure of at least 140 mm Hg systolic or 90 mm Hg diastolic or use of antihypertensive drugs. 
All between-sex differences were significant (P < 0.05) with the exception of smoking (P = 0.13), age (P = 0.63), prevalence of hyperten-
sion (P = 0.07) and diabetes mellitus (P = 0.13), and 24-hour systolic average real variability (P = 0.32) in the discovery dataset and serum 
 cholesterol (P = 0.33) and prevalence of antihypertensive drug intake (P = 0.3) in the test dataset.
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revascularization, 15 deaths from ischemic heart disease, 5 
sudden deaths, 46 nonfatal heart failures, 8 fatal heart fail-
ures, 4 deaths from peripheral arterial disease, and 3 unspec-
ified cardiovascular deaths.
The median number of BP readings in the discovery data-
set was 81 (5th–95th percentile = 80–84). In general, mean 
ARV increased with decreasing number of BP measure-
ments. In addition, the repeatability and relative repeatability 
coefficients increased, and Pearson correlation coefficients 
decreased with fewer BP readings, indicating reduced con-
cordance with ARV based on full recordings as more read-
ings were excluded (Table 2).
When the full recordings were used, the sex- and age-
adjusted HRs associated with an increase in systolic ARV by 
1 SD were 1.18 (95% confidence interval (CI) = 1.04–1.33; 
P = 0.01) for total mortality and 1.20 (95% CI = 1.04–1.39; 
P  =  0.01) for the composite cardiovascular endpoint. For 
diastolic BP, these HRs were 1.16 (95% CI  =  1.02–1.32; 
P = 0.02) and 1.15 (95% CI = 0.99–1.33; P = 0.07). In general, 
reducing the number of BP readings led to smaller HRs (Tables 
3 and 4; Figure  1) and, consequently, a weaker association 
between the 10-year risk and ARV (Figures 2 and 3). 
However, the HRs remained fairly constant down to 40–48 
BP readings. For total mortality, the HRs associated with both 
Table 2. Concordance between average real variability computed from full and reduced recordings in the discovery database
Minimum number of 
blood pressure readings
Systolic blood pressure Diastolic blood pressure
Mean ARV  
(SD)
Delta,  
mm Hg
RC,  
mm Hg RRC, % r
Mean ARV 
(SD)
Delta,  
mm Hg
RC,  
mm Hg RRC, % r
80 11.74 (2.45) NA NA NA NA 7.79 (1.36) NA NA NA NA
72 11.95 (2.55) 0.20 1.58 16.0 0.95 7.97 (1.42) 0.18 1.07 19.6 0.93
64 12.21 (2.66) 0.47 2.33 23.4 0.90 8.16 (1.50) 0.37 1.54 28.0 0.86
56 12.54 (2.90) 0.80 3.04 29.5 0.85 8.42 (1.62) 0.63 1.90 33.5 0.81
48 12.84 (3.00) 1.09 3.70 35.9 0.79 8.67 (1.72) 0.89 2.36 41.2 0.73
40 13.12 (3.21) 1.37 4.45 42.2 0.72 8.93 (1.86) 1.14 2.81 47.8 0.66
32 13.48 (3.40) 1.74 7.28 77.6 0.26 9.23 (2.01) 1.45 4.41 84.1 0.18
Abbreviations: ARV, average real variability over 24 hours; Delta, ARV based on reduced recording minus ARV based on full recording (at 
least 80 measurements); NA, not applicable; RC, repeatability coefficient for the correspondence between the reduced and full recordings; 
RRC, relative repeatability coefficient for the correspondence between the full and reduced recordings.
Table 3. Standardized hazard ratios for all-cause mortality associated with mean 24-hour blood pressure and average real variability 
calculated from full and reduced recordings in the discovery dataset
Minimum 
number of BP 
readings
Systolic BP Diastolic BP
Mean 24-h BP Average real variability Mean 24-h BP Average real variability
Hazard ratio  
(95% CI) Delta, %
Hazard ratio  
(95% CI) Delta, %
Hazard ratio  
(95% CI) Delta, %
Hazard ratio  
(95% CI) Delta, %
80 1.17 (1.04–1.33)** NA 1.18 (1.04–1.33)** NA 1.18 (1.04–1.34)** NA 1.16 (1.02–1.32)** NA
72 1.17 (1.03–1.32)** −0.3 1.16 (1.02–1.32)** −1.3 1.18 (1.04–1.35)**  0.3 1.14 (1.00–1.30)** −1.5
64 1.17 (1.04–1.33)**  0.0 1.15 (1.02–1.29)** −2.5 1.18 (1.03–1.34)** −0.2 1.12 (0.99–1.27)*** −3.3
56 1.16 (1.03–1.32)** −0.9 1.16 (1.03–1.31)** −1.6 1.16 (1.02–1.32)** −1.9 1.14 (1.00–1.29)** −1.9
48 1.17 (1.03–1.32)** −0.6 1.16 (1.03–1.31)** −1.6 1.18 (1.04–1.35)**  0.2 1.14 (1.00–1.29)** −2.0
40 1.18 (1.04–1.33)*  0.2 1.06 (0.93–1.20) −10.2 1.18 (1.04–1.35)**  0.4 1.11 (0.98–1.25)*** −4.5
32 1.06 (0.94–1.21) −9.2 1.01 (0.89–1.14) −14.2 0.98 (0.86–1.12) −17.0 1.01 (0.90–1.15) −12.5
Standardized hazard ratios (95% confidence intervals (CIs)) express the risk in all-cause mortality associated with 1 SD increase in the 
24-hour blood pressure (BP) or the 24-hour average real variability. The SD of the 24-hour systolic BP was 12.77 mm Hg for the full recordings 
(at least 80 readings) and 12.79, 12.81,12.82,1 2.90, 12.92, and 12.83 mm Hg for the reduced recordings including at least 72, 64, 56, 48, 40, 
and 32 readings, respectively. For systolic average real variability, these SDs were 2.45, 2.55, 2.66, 2.45, 3.00, 3.21, and 3.40 mm Hg, respec-
tively. The corresponding SDs for the 24-hour diastolic BP and the diastolic average real variability were 8.38, 8.38, 8.42, 8.43, 8.46, 8.51, and 
8.46 mm Hg; and 1.36,1.42, 1.50, 1.62, 1.72, 1.86, and 2.01 mm Hg, respectively. All hazard ratios were computed by Cox regression and were 
adjusted for sex and age. Delta is the percent difference between the hazard ratio calculated from the reduced recording and the hazard ratio 
calculated from the full recording. 
Abbreviation: NA, not applicable.
Significance of the hazard ratios: *P < 0.01; **P < 0.05; ***0.05 ≤ P < 0.10.
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Figure 1. Standardized hazard ratios (95% confidence intervals (CI)) relating all-cause mortality (a and c) and all fatal combined with nonfatal cardio-
vascular events (b and d) to systolic (a and b) and diastolic (c and d) average real variability over 24 hours calculated from full (at least 80 readings) and 
reduced recordings with a minimum of 72, 64, 56, 48, 40, or 32 readings. Hazard ratios were adjusted for sex and age and express the risk per SD increase 
in average real variability in the 1,254 subjects included in the discovery dataset.
Table 4. Standardized hazard ratios for the composite cardiovascular endpoint associated with mean 24-hour blood pressure and average 
real variability calculated from full and reduced recordings in the discovery dataset
Minimum 
number of BP 
readings
Systolic BP Diastolic BP
Mean 24-h BP Average real variability Mean 24-h BP Average real variability
Hazard ratio  
(95% CI) Delta, %
Hazard ratio  
(95% CI) Delta, %
Hazard ratio  
(95% CI) Delta, %
Hazard ratio  
(95% CI) Delta, %
80 1.39 (1.21–1.60)* NA 1.20 (1.04–1.39)*** NA 1.30 (1.12–1.52)** NA 1.15 (0.99–1.33)**** NA
72 1.40 (1.21–1.61)*  0.3 1.20 (1.03–1.39)*** −0.4 1.30 (1.12–1.51)** −0.2 1.14 (0.98–1.32)**** −0.9
64 1.40 (1.22–1.61)*  0.6 1.17 (1.02–1.35)*** −2.7 1.30 (1.12–1.51)** −0.2 1.11 (0.95–1.28) −3.6
56 1.38 (1.20–1.60)* −0.6 1.17 (1.02–1.35)*** −2.6 1.29 (1.12–1.50)** −0.8 1.09 (0.94–1.26) −5.2
48 1.38 (1.20–1.60)* −0.6 1.15 (1.00–1.32)**** −4.6 1.30 (1.12–1.51)** −0.4 1.10 (0.95–1.27) −4.3
40 1.41 (1.23–1.63)*  1.4 1.11 (0.96–1.28) −7.8 1.29 (1.11–1.50)** −1.0 1.09 (0.94–1.26) −5.2
32 1.11 (0.96–1.29) −20.3 1.02 (0.88–1.18) −15.1 1.04 (0.90–1.21) −20.1 1.00 (0.86–1.16) −12.9
Standardized hazard ratios (95% confidence intervals (CIs)) express the risk in all-cause mortality associated with 1 SD increase in the 
24-hour blood pressure (BP) or the 24-hour average real variability. The SD of the 24-hour systolic BP was 12.77 mm Hg for the full recordings 
(at least 80 readings) and 12.79, 12.81,12.82,1 2.90, 12.92, and 12.83 mm Hg for the reduced recordings including at least 72, 64, 56, 48, 40, 
and 32 readings, respectively. For systolic average real variability, these SDs were 2.45, 2.55, 2.66, 2.45, 3.00, 3.21, and 3.40 mm Hg, respec-
tively. The corresponding SDs for the 24-hour diastolic BP and the diastolic average real variability were 8.38, 8.38, 8.42, 8.43, 8.46, 8.51, and 
8.46 mm Hg; and 1.36,1.42, 1.50, 1.62, 1.72, 1.86, and 2.01 mm Hg, respectively. All hazard ratios were computed by Cox regression and were 
adjusted for sex and age. Delta is the percent difference between the hazard ratio calculated from the reduced recording and the hazard ratio 
calculated from the full recording.
Abbreviation: NA, not applicable.
Significance of the hazard ratios: *P < 0.0001; **P < 0.001; ***P < 0.05; ****0.05 ≤ P < 0.10.
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systolic and diastolic ARV were significant (P  <  0.05) and 
>10% when ARV was calculated with at least 48 BP readings. 
Similarly, for the composite cardiovascular endpoint, reduced 
recordings composed of at least 48 readings generally yielded 
HRs ≥1.10 for both systolic and diastolic ARV. However, 
for systolic ARV statistical significance was lost when <56 
readings were used. For diastolic ARV, the HRs were not 
significant either for the full or reduced recordings.
Figure 2. Ten-year risk (%) of death in relation to systolic (left panel) and diastolic (right panel) average real variability over 24 hours (ARV) calculated 
from full (at least 80 readings) and reduced recordings with a minimum of 72, 64, 56, 48, 40, or 32 readings in the discovery cohort. The analyses were 
standardized to the midpoint (mean or ratio) of the distributions in the discovery cohort of sex and age. P values are for the independent effect of ARV 
calculated from full (P80) and reduced (P72, P64, P56, P48, P40, and P32) recordings.
Figure 3. Ten-year risk (%) of a fatal or nonfatal cardiovascular (CV) event in relation to systolic (left panel) and diastolic (right panel) average real vari-
ability over 24 hours (ARV) calculated from full (at least 80 readings) and reduced recordings with a minimum of 72, 64, 56, 48, 40, or 32 readings in the 
discovery cohort. The analyses were standardized to the midpoint (mean or ratio) of the distributions in the discovery cohort of sex and age. P values are 
for the independent effect of ARV calculated from full (P80) and reduced (P72, P64, P56, P48, P40, and P32) recordings.
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Test dataset
The results based on artificially reduced ambulatory BP 
recordings were confirmed using a larger sample of 5,353 
subjects, whose ambulatory BP recordings included at least 
48 BP readings. The test dataset included 879 residents of 
Copenhagen, Denmark, who were not included in the discov-
ery dataset;8 954 subjects from Noorderkempen, Belgium;17 
925 older men from Uppsala, Sweden;9 242 subjects from 
Novosibirsk, the Russian Federation;10,11 422 inhabitants 
of Ohasama, Japan;15 344 villagers from JingNing County, 
China;12 161 subjects from Pilsen, the Czech Republic;11 265 
subjects from Dublin, Ireland;14 310 subjects from Padova, 
Italy;11 308 subjects from Kraków, Poland;11 and 543 older 
subjects from Maracaibo, Venezuela.13 Compared with the 
discovery dataset, the 2,440 women and 2,913 men included 
in the test dataset were younger (54.0 ± 16.1 years) and had 
lower body mass index (25.6 ± 4.1 kg/m2) and lower 24-hour 
ambulatory BP (125.1 ± 14.5 mm Hg systolic, 73.8 ± 8.4 mm 
Hg diastolic). The test dataset included a similar proportion 
of hypertensive patients (47.5%) but more subjects receiv-
ing antihypertensive drug treatment (21.3%). The test data-
set included smaller proportions of smokers (27.6%) and 
subjects reporting alcohol intake (54.0%) and a higher pro-
portion of subjects with a history of cardiovascular disease 
(16.2%) or diabetes mellitus (7.3%). The median number of 
BP readings per recording in the test dataset was 64 (5th–
95th percentile = 48–79).
Median follow-up for participants in the test dataset was 
10.2  years (5th–95th percentile  =  2.5–18.4  years), ranging 
from 2.5  years (5th–95th percentile  =  2.3–2.6  years) in 
JinNing to 17.6 years (5th–95 percentile = 6.4–20.4 years) in 
Noorderkempen. During 55,856 person-years of follow-up, 
806 participants died (14.4 per 1,000 person-years), and 
696 experienced a fatal or nonfatal cardiovascular event 
(12.9 per 1,000 person-years). The cause of death was 
cardiovascular in 335 participants. Considering cause-
specific first cardiovascular events, the incidences of fatal and 
nonfatal stroke were 39 and 200, respectively. Cardiac events 
consisted of 172 fatal and 265 nonfatal events, including 143 
nonfatal cases of acute myocardial infarction, 155 deaths 
from ischemic heart diseases, 6 sudden deaths, 11 fatal and 
84 nonfatal cases of heart failure, and 38 cases of surgical or 
percutaneous coronary revascularization.
The standardized HRs relating outcome to ARV, adjusted 
for cohort, sex, age, body mass index, smoking status, alco-
hol intake, serum cholesterol, history of cardiovascular dis-
ease, and treatment with antihypertensive drugs, showed 
that systolic and diastolic ARV significantly (P  <  0.0005) 
predicted total, cardiovascular, and cardiac mortality and 
fatal plus nonfatal cardiovascular and cerebrovascular events 
(Table  5). Systolic but not diastolic ARV also significantly 
(P  =  0.003) predicted cardiac events. However, after addi-
tional adjustment for 24-hour mean BP, systolic and diastolic 
ARV significantly (P < 0.01) predicted only total, cardiovas-
cular, and cardiac deaths. In addition, higher diastolic ARV 
was significantly (P = 0.009) related to the incidence of fatal 
plus nonfatal cerebrovascular outcomes. The R2 statistics for 
adding ARV to BP level and other covariables as combined 
predictors of the composite cardiovascular endpoint were 
0.035% and 0.031% for systolic and diastolic ARV, respec-
tively (Supplementary Table S2)
DISCUSSION
The technique of noninvasive ambulatory BP monitor-
ing has rapidly expanded during the past 30 years, both as 
an instrument in clinical research and as a diagnostic tool 
in clinical practice. Several studies have examined the effect 
of intermittent readings on the accurate assessment of true 
24-hour average BP.23,25–27 Despite numerous studies that 
have reported on the predictive value of short-term BP 
variability,1,2,5,28,29 the frequency and/or number of BP read-
ings necessary to accurately estimate variability of 24-hour 
BP has not been assessed before. Di Rienzo et al.25 demon-
strated that accurate estimation of 24-hour average BP could 
be achieved at intervals as great as 30–60 minutes; however, 
short-term BP variability at sampling intervals of ≥15 min-
utes, as assessed by within-subject SD, deviated considerably 
from beat-to-beat analysis.
Several studies found that both short-term reading-to-
reading23,25–27 and long-term visit-to-visit30–33 BP variability, 
estimated by ambulatory BP monitoring, are poorly repro-
ducible, which could explain the rather diverse findings 
regarding its clinical value as a predictor of cardiovascular 
outcomes.34 Several factors are potentiality responsible for 
the poor reproducibility of BP variability. First, it could be 
influenced by day-to-day variation in the subject’s activities. 
Second, predictions could have been based on insufficient 
numbers of BP readings; a small sample size increases the 
potential error in estimating the true variance.25 Finally, 
although the SD is a convenient measure, it might not be 
the most accurate method to assess BP variability.1–3,5,30 To 
address the latter 2 problems, in the present IDACO study, 
BP variability was assessed using ARV,1,2 and the number of 
BP readings needed to make accurate risk predictions was 
formally tested.
The most important observation was that the number of 
BP readings used to calculate ARV affected both its repro-
ducibility and its strength as a predictor of mortality and car-
diovascular outcomes. Concordance between ARV values 
based on full and randomly reduced BP measurements and 
predictive value declined significantly as more BP readings 
were excluded. A possible explanation is that within-subject 
ARV might increase when calculated from fewer BP read-
ings, masking differences between subjects that actually have 
high or low BP variability.
In a discovery dataset that included >1,000 randomly 
recruited subjects with a median of 12.4 years of follow-up, 
a minimum of approximately 48 BP readings was necessary 
to accurately estimate ARV. This conclusion was supported 
using a test dataset with >5,000 subjects, randomly recruited 
from 11 populations, with a median of 10.2  years of 
follow-up. Using this minimum number of BP readings, 
both systolic and diastolic ARV were significant predictors of 
mortality and cardiovascular endpoints in models adjusted 
for 24-hour BP level and other covariables. These results 
are in partial agreement with those of Hansen et al.,2 who 
computed ARV with a less restrictive minimum number 
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of BP readings (at least 10  daytime and 5 nighttime BP 
readings). They found that both systolic ARV and diastolic 
ARV were significant and independent predictors of total 
and cardiovascular mortality and of fatal combined with 
nonfatal cardiovascular events. However, this study did not 
find that ARV was a significant and independent predictor of 
cardiac mortality in a fully adjusted model.2
Although prognostic value1,2,5 and reproducibility30 are 
better for ARV than for other variability indexes, such as SD 
or weighted SD,35 ARV computed with at least 48 BP read-
ings accounted for <0.1% of risk of a composite cardiovas-
cular event, beyond the proportion explained by 24-hour 
BP level. Furthermore, although the precision of ARV 
could be improved by increasing the number of measure-
ments, increasing the number of BP readings beyond 48 
readings in clinical practice seems inconvenient, because 
this makes 24-hour ambulatory BP monitoring less com-
fortable. Therefore, accurate assessment of BP variability 
might have greater relevance for research than for clinical 
purposes. It could produce unconfounded information on 
mechanisms of homeostatic control of BP under physiologi-
cal and pathological conditions, such as essential and sec-
ondary hypertension, congestive heart failure, diabetes, and 
renal insufficiency. A  reliable assessment of BP variability, 
with an adequate minimum number of BP readings could 
also be used to design studies to improve the diagnosis and 
prognosis of hypertension by providing better information 
on end-point organ damage associated with high BP values 
and could be used to assess the efficacy of antihypertensive 
agents.36 Finally, accurate calculation of ARV could be useful 
in the development of therapeutic drugs to reduce BP vari-
ability, which might represent a new strategy for the treat-
ment of hypertension.37
Despite the statistical power and the consideration of fatal 
and nonfatal events, this study had several potential limita-
tions. First, although the test dataset was composed of 11 
population-based cohorts from 3 continents, our results 
might not be applicable to all ethnic groups, particularly to 
Africans of black ancestry or African Americans, although 
Veerabhadrappa et  al.6 showed that ARV was significantly 
Table 5. Multivariable-adjusted standardized hazard ratios associated with average real variability in the test dataset
Outcome (number of events)
24-h average real variability
Systolic blood  
pressure, HR (95% CI)
Diastolic blood  
pressure, HR (95% CI)
Mortality
 Total (n = 806)
  Adjusted 1.21 (1.12–1.30)* 1.16 (1.08–1.23)*
  Fully adjusted 1.12 (1.03–1.21)*** 1.12 (1.04–1.20)***
 Cardiovascular (n = 335)
  Adjusted 1.33 (1.20–1.48)* 1.27 (1.16–1.38)*
  Fully adjusted 1.17 (1.04–1.31)*** 1.19 (1.08–1.30)**
 Cardiac (n = 335)
  Adjusted 1.38 (1.20–1.59)* 1.24 (1.10–1.40)**
  Fully adjusted 1.24 (1.06–1.45)*** 1.19 (1.05–1.35)***
Fatal and nonfatal events combined
 All cardiovascular (n = 696)
  Adjusted 1.19 (1.10–1.29)* 1.13 (1.06–1.21)**
  Fully adjusted 1.06 (0.98–1.15) 1.05 (0.98–1.13)
 Cardiac (n = 437)
  Adjusted 1.17 (1.06–1.29)*** 1.04 (0.95–1.14)
  Fully adjusted 1.05 (0.94–1.17) 0.98 (0.89–1.09)
 Cerebrovascular (n = 239)
 Adjusted 1.26 (1.11–1.43)** 1.29 (1.16–1.42)*
 Fully adjusted 1.08 (0.95–1.23) 1.16 (1.04–1.29)***
Values are standardized hazard ratios (HRs) (95% confidence intervals (CIs)) associated with 1 SD increase in average real variability (ARV) 
calculated using at least 48 readings. The SD of the ARV was 3.32 mm Hg for systolic blood pressure and 2.66 mm Hg for diastolic blood pres-
sure. All HRs were computed by Cox regression, stratified for cohort, and adjusted for sex, age, body mass index, smoking status, alcohol 
intake, serum cholesterol, history of cardiovascular disease, and treatment with antihypertensive drugs. Fully adjusted models were additionally 
adjusted for the 24-hour blood pressure level.
Significance of the hazard ratios: *P < 0.0001; **P < 0.001; ***P < 0.01.
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correlated with target organ damage in African Americans. 
Second, we and most other investigators used intermittent 
techniques of ambulatory BP monitoring, which are less 
precise than continuous BP monitoring for measuring short-
term BP variability. Unfortunately, intra-arterial recordings 
or continuous recordings of the arterial signal at the finger 
are difficult, if not impossible, to implement in large epide-
miological studies. Third, because the goal was to estimate 
an appropriate minimum range of BP readings for calculat-
ing ARV in a reproducible manner, relatively large numbers 
of BP measurements were omitted, ultimately producing 
low concordances. However, Kikuya et al.22 excluded fewer 
BP readings and found that the parameter under study lost 
prognostic significance only when ≥16 readings were ran-
domly excluded.
In summary, 48 BP readings over 24 hours is sufficient 
to compute ARV without meaningfull loss of prognostic 
information. This number of BP readings should be 
considered for research purposes when trying to assess the 
effects of BP variability on outcome variables or the effects of 
an intervention on BP variability using ARV as an estimate. 
Usefulness of ARV in the clinical setting remains to be 
determined, but ARV needs to be computed with enough 
measurements to retain its prognostic value.
SUPPLEMENTARY MATERIAL
Supplementary materials are available at American Journal 
of Hypertension (http://ajh.oxfordjournals.org).
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EXPANDED METHODS  
Study population  
The International Database on Ambulatory blood pressure monitoring in relation to Cardio-
vascular Outcomes (IDACO) was constructed, as previously described.1 Studies were eligi-
ble for inclusion if 1) they involved a random population sample, 2) baseline information on 
ambulatory blood pressure and cardiovascular risk factors was available, 3) follow-up includ-
ed both fatal and nonfatal outcomes, and 4) they were reported in peer-reviewed publica-
tion.2-11  
A subset of the Copenhagen cohort2,12,13 was selected as the discovery dataset for the 
present study. In 1982 to 1984, this cohort participated in the MONItoring of trends and de-
terminants in Cardiovascular Disease (MONICA 1) health survey.14  Participants were se-
lected to represent an equal number of men and women aged 30, 40, 50, and 60 years. 
Eventually, 3785 (83%) participated. In 1993 to 1994, the participants were invited to be ex-
amined again and to have their ambulatory blood pressure recorded. A total of 2656 (70%) 
subjects were willing to participate and gave written informed consent. At the repeat exami-
nation, which is considered the baseline examination in IDACO, the subjects were 41, 51, 61 
and 71 years old. In 2006, information on the incidence of fatal and nonfatal outcomes was 
collected. A total of 2311 subjects met the criteria for inclusion into the IDACO database. All 
Copenhagen subjects with at least  80 readings during 24 hours were included in the discov-
ery dataset (n=1254). 
Subjects from the Montevideo cohort10 were not included in the test dataset because their 
recordings included less than 48 readings.  
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Blood pressure measurements   
Conventional blood pressure was measured by trained observers with a mercury sphyg-
momanometer,2-6,8,11 with validated auscultatory9 (USM-700F, UEDA Electronic Works, To-
kyo, Japan) or oscillometric7 (DINAMAP 8100, Critikon Inc., Tampa, USA) devices, using the 
appropriate cuff size, with participants in the sitting2,4-9,11 or supine3 position.  Conventional 
blood pressure was the average of 2 consecutive readings obtained either at the person’s 
home4-6,11 or at an examination center.2,3,7-9  Office hypertension was a conventional blood 
pressure of at least 140 mm Hg systolic or 90 mm Hg diastolic or the use of antihypertensive 
drugs.15  We programmed portable monitors to obtain ambulatory blood pressure readings at 
30 minute intervals throughout the whole day,8,9 or at intervals ranging from 152,7 to 303 
minutes during daytime and from 302,7 to 603 minutes at night. The devices implemented an 
auscultatory algorithm (Accutracker II) in Uppsala3 or an oscillometric technique (SpaceLabs 
90202 and 90207, Nippon Colin, and  ABPM 630) in the other cohorts.2,4-9,11   
The same SAS macro processed all ambulatory recordings, which generally stayed unedit-
ed.  The Ohasama recordings were edited sparsely according to previously published crite-
ria.16  Within individual subjects, we weighted the means of the ambulatory blood pressure 
by the interval between readings.1   
While accounting for the daily pattern of activities of the participants,17 we defined daytime 
as the interval ranging from 8000 h to 2200 h in Europeans2-5,8,11 and South Americans,7 
and from 0600 h to 2000 h in Asians.6,9  The corresponding night-time intervals ranged from 
2200 to 0800 h2-5,8,11 and from 2000 h to 0600 h.6,9   The fixed intervals eliminated the 
morning and evening transition periods when blood pressure changes rapidly, resulting in 
daytime and nighttime blood pressure levels that were within 1-2 mm Hg of the waking and 
sleeping levels.17  
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Other measurements  
A questionnaire was administered in each cohort to obtain information on each subject’s 
medical history and smoking and drinking habits. Body mass index was body weight in kilo-
grams divided by height in meters squared. Serum cholesterol and blood glucose were 
measured by automated enzymatic methods. Diabetes mellitus the use of antidiabetic drugs, 
a fasting blood glucose concentration of at least 7.0 mmol/L,2-5,7-9,11 a random blood glu-
cose concentration of at least 11.1 mmol/L,6,9,11 a self-reported diagnosis,6,7,11 or diabetes 
documented in practice or hospital records.7 
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Table S1.  International classification of diseases (ICD) codes applied in each IDACO cohort  
Cohort  Stroke  Myocardial infarction Angina pectoris  Heart failure  
Copenhagen  ICD8 430-434  
and 436,  
ICD10 I60-I64  
ICD8 410,  
ICD10 I21-I22  
ICD8 411-414,  
ICD10 I20 and I23-I25  
ICD8 427.0, 427.1, 428.0, 
429.0, 519.1 and 782.4,  
ICD10 I50 and J81  
Noorderkempen  ICD8 430-434,  
436 and 438  
ICD8 410   ICD8 413  ICD8 427.0, 427.1, 428.0, 
429.0, 519.1 and 782.4  
Uppsala  ICD9 430-434  
and 436,  
ICD10 I60-I64  
ICD9 410,  
ICD10 I21 
ICD9 413 and 411.1, ICD10 I20  ICD9 429, ICD10 I50 
Dublin  ICD9 430-434  
 and 436  
ICD9 410 and 412  ICD9 413, 411.1  
and 414  
ICD9 428  
Novosibirsk  ICD9 430-434  
and 436  
ICD9 410 and 412  ICD9 413 and 411.1 ICD9 428  
Pilsen  ICD9 430-434  
and 436  
ICD9 410 and 412  ICD9 413 and 411.1 ICD9 428  
Padova  ICD9 430-434  
and 436  
ICD9 410 and 412  ICD9 413 and 411.1 ICD9 428  
Kraków  ICD9 430-438  ICD9 410  ICD9 413  ICD9 428.0-428.4  
Ohasama  ICD10 I60-I64  NA NA NA 
JingNing   ICD9 430-431 
and 434  
ICD9 410  ICD9 413 ICD9 428, 427.0  
and 427.1  
Maracaibo ICD9 430-434  ICD9 410 and 412  NA ICD9 428  
NA, no tassessed because of low incidence in the Ohasama and Maracaibo cohorts.  
Influence of Sampling Frequency on ABP variability  -9-  
 
Table S2.  Risk of a composite cardiovascular event explained by Cox regression  
Strata  Systolic Blood Pressure   Diastolic Blood Pressure  
  -2 Log Likelihood  P  R²(%)   -2 Log Likelihood  P  R²(%)  
Null model  8806.003 NA NA  8806.003 NA NA 
Basic model  8289.391 < 0.0001 9.20  8289.391 < 0.0001 9.20 
Basic model+24-hour BP  8207.439 < 0.0001 1.52  8240.880 < 0.0001 0.902 
Basic model+24-hour BP+ARV  8205.572 0.17 0.035  8239.210 0.19 0.031 
The basic Cox model was stratified for cohort and included the following covariates: sex, age, body mass index, current smoking status, alcohol intake, serum 
cholesterol, history of cardiovascular disease, and treatment with antihypertensive drugs.  P-values are for improvement of the fit across nested models.  R² is 
the generalized R-squared for the improvement of the fit across nested models. 
NA,  not applicable; BP, blood pressure; ARV, average real variability 
 
